Clinical Evaluation of Etafilcon A With Ketotifen

• etafilcon A with ketotifen (Combination product): Etafilcon A with ketotifen
• 1-Day ACUVUE (Device): 1-Day ACUVUE

Primary outcomes

• Monocular Contact Lens-corrected Distance Visual Acuity (Per-Protocol Population) [Baseline (Visit 1) and 1-week follow up (Visit 2)]: Monocular contact lens-corrected distance visual acuity was assessed using a logMAR visual acuity scale. This was evaluated for each eye, under high luminance and high contrast conditions at 4 meters from ETDRS charts. Distance visual acuity was reported by lens type and visit.
• Monocular Contact Lens-corrected Distance Visual Acuity (Modified Intent-to-Treat Population) [Baseline (Visit 1) and 1-week follow up (Visit 2)]: Monocular contact lens-corrected distance visual acuity was assessed using a logMAR visual acuity scale. This was evaluated for each eye, under high luminance and high contrast conditions at 4 meters from ETDRS charts. Distance visual acuity was reported by lens type and visit.

Secondary outcomes

• The Number of Eyes With Clinically Significant Slit Lamp Findings [Up to 1-Week Follow-up]: Slit lamp findings were assessed using a biomicroscope for each subject eye at all scheduled and unscheduled visits. Clinical significant slit lamp findings are defined as Grade 3 or Grade 4. (Grade 0=None, Grade 1=Trace, Grade 2=Mild, Grade 3=Moderate and Grade 4= Severe). The data was dichotomized as 1=Grade 3 or Grade 4 and 0, otherwise. The number of eyes with clinically significant slit lamp findings for each lens type was reported.
• The Number of Eyes With Unacceptable Lens Fitting [Up to 1-Week Follow-up]: Lens fit was assessed for each subject and eye using a biomicroscope. Unacceptable lens fit was assessed at all scheduled and unscheduled visits. A subject was deemed to have an unacceptable lens fitting if they met any of the following criteria: (1) Limbal exposure at primary gaze with extreme eye movement, (2) edge lift, (3) excessive movement in primary up gaze, (4) insufficient movement in all three of the following conditions: primary gaze, up gaze and push up test. The number of eyes with unacceptable lens fitting was reported for each lens type.

Sex: All, ages: 18 Years to 40 Years, accepts healthy volunteers

Inclusion Criteria:

* Potential subjects must satisfy all of the following criteria to be enrolled in the study

  1. The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
  2. Appear able and willing to adhere to the instructions set forth in this clinical protocol.
  3. Between 18 and 39 (inclusive) years of age at the time of baseline visit.
  4. The subject must be a habitual lens wearer for a least 6 days/week and for a minimum of 8 hours per day over the last month.
  5. The subject's contact lens correction must be in the range of -1.00 D to -6.00 D (inclusive) in each eye.
  6. The subject's refractive cylinder must be 1.00 D or less in each eye.
  7. Have a spherocylindrical best corrected visual acuity of 20/30 or better in each eye (Snellen Visual Acuity).

     Exclusion Criteria:
* Potential subjects who meet any of the following criteria will be excluded from participating in the study:

  1. Currently pregnant or lactating.
  2. Any systemic disease (e.g., Sjögren's Syndrome), allergies, infectious disease (e.g., hepatitis, tuberculosis), contagious immunosuppressive diseases (e.g., HIV), autoimmune disease (e.g. rheumatoid arthritis), or other diseases, by self-report, which are known to interfere with contact lens wear and/or participation in the study.
  3. Use of systemic medications (e.g., chronic steroid use) that are known to interfere with contact lens wear.
  4. Any ocular allergies, infections or other ocular abnormalities that are known to interfere with contact lens wear and/or participation in the study. This may include, but not be limited to entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, or corneal distortion.
  5. Any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear, history of strabismus, or current monovision, multi-focal, or toric contact lens correction.
  6. Any current use of rewetting drops or ocular medication.
  7. Any previous, or planned (during the course of the study) ocular surgery (e.g., radial keratotomy, PRK, LASIK, etc.).
  8. Any grade 3 or greater slit lamp findings (e.g., edema, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival injection) on the FDA Biomicroscopy Scale.
  9. Any previous history or signs of a contact lens-related corneal inflammatory event (e.g., past peripheral ulcer or round peripheral scar), or any other ocular abnormality that would contraindicate contact lens wear.
  10. Any known hypersensitivity or allergic reaction to ketotifen.
  11. Participation in any eye drop, contact lens or lens care product clinical trial within 14 days prior to study enrollment.
  12. Employee or immediate family member of an employee of clinical site (e.g., Investigator, Coordinator, Technician).

Participant flow

Outcome results

• Monocular Contact Lens-corrected Distance Visual Acuity (Per-Protocol Population) (Primary), Mean, logMAR: Etafilcon A With Ketotifen -0.111 +/- 0.0702; Etafilcon A -0.109 +/- 0.0809
• Monocular Contact Lens-corrected Distance Visual Acuity (Modified Intent-to-Treat Population) (Primary), Mean, logMAR: Etafilcon A With Ketotifen -0.109 +/- 0.0740; Etafilcon A -0.110 +/- 0.0806
• The Number of Eyes With Clinically Significant Slit Lamp Findings (Secondary), Number, Number of Eyes: Etafilcon A With Ketotifen 0; Etafilcon A 0
• The Number of Eyes With Unacceptable Lens Fitting (Secondary), Number, eyes: Etafilcon A With Ketotifen 0; Etafilcon A 1

Adverse events

Time frame: Throughout the entire duration of the study. Approximately 1-Week per subject.

• Study Protocol (PDF, 2017-10-31)
• Statistical Analysis Plan (PDF, 2018-03-29)